Clinical Trials Logo

Clinical Trial Summary

This is a phase 2 open-label study to test the safety and effectiveness of combining pembrolizumab and bendamustine in patients with relapsed (cancer that has come back or started getting worse) or refractory (cancer that is not responding or has stopped responding to treatment) Hodgkin lymphoma.


Clinical Trial Description

Pembrolizumab and bendamustine will be explored as a safe and effective treatment for these patients. Although current treatment options are available for patients in the relapsed state, once these therapies fail or are not tolerated, treatment options are quite limited. Pembrolizumab and bendamustine have both shown activity when used as a single agent as treatment for Hodgkin Lymphoma. Their side effect profiles also do not overlap, which makes them ideal to combine, with an intent to increase the amount and duration of complete responses while limiting the toxicities experienced by patients. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04510636
Study type Interventional
Source University Health Network, Toronto
Contact John Kuruvilla, M.D.
Phone 416-946-2821
Email john.kuruvilla@uhn.ca
Status Recruiting
Phase Phase 2
Start date December 20, 2021
Completion date June 1, 2026

See also
  Status Clinical Trial Phase
Active, not recruiting NCT03336931 - PRecISion Medicine for Children With Cancer
Completed NCT00530192 - Molecular Profiling Protocol (SCRI-CA-001) Phase 0
Recruiting NCT05852717 - Safety and Efficacy of Epcoritamab With Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chemotherapy in Relapsed Refractory Large B-cell Lymphoma Phase 2
Recruiting NCT06229340 - Leflunomide or Combination of MEK Inhibitor and Hydroxychloroquine for Refractory Patients With RAS Mutations Phase 2
Completed NCT00551850 - A Safety Study of an Oral EGFR Inhibitor, AV-412, Administered Three Times Weekly in Advanced Solid Tumor Patients Phase 1
Recruiting NCT06104488 - A Study of Avutometinib for People With Solid Tumor Cancers Phase 1
Terminated NCT04092179 - Study of Enasidenib and Venetoclax in IDH2-Mutated Blood Cancers Phase 1/Phase 2
Recruiting NCT06184035 - A Dose Escalation and Expansion Study of [177Lu]Lu-SN201 in Participants With Advanced Cancer Phase 1/Phase 2
Recruiting NCT06024603 - Individualized Treatments in Adults With Relapsed/Refractory Cancers N/A
Recruiting NCT05859074 - A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer Phase 1
Recruiting NCT05864144 - A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors Phase 1/Phase 2
Active, not recruiting NCT03187288 - Study of CFI-400945 Fumarate in Patients With Relapsed or Refractory AML or MDS Phase 1
Terminated NCT01320280 - BIBW 2992 (Afatinib) for the Treatment of Patients With HER2-positive, Hormone-refractory Prostate Cancer Phase 2
Completed NCT03441100 - TCR-engineered T Cells in Solid Tumors: IMA202-101 Phase 1
Recruiting NCT05359445 - IMA401 TCER® in Recurrent and/or Refractory Solid Tumors Phase 1
Recruiting NCT03686124 - ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors Phase 1
Recruiting NCT04337580 - Fatty Acid Synthase Inhibition in Castration Refractory Prostate Cancer Phase 2
Active, not recruiting NCT04310345 - Impact of Human-Animal Interactions on Children With Life-Threatening Conditions and Their Parents N/A
Recruiting NCT05669430 - A Study of GV20-0251 in Patients With Solid Tumor Malignancies Phase 1
Not yet recruiting NCT06208657 - Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent Cancer Phase 1/Phase 2